A study to evaluate the efficacy and safety of Apremilast, Etanercept and placebo, in subjects with moderate to severe plaque psoriasis
- Registry ID
- EUCTR2012-000859-14
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Celgene Corporation
- Start date
- 2012-10-09
- Completion date
- 2016-04-04
- Last update
- 2026-08-16
Conditions
- Moderate to severe plaque psoriasis
- Psoriasis, a chronic inflammatory skin disorder, estimated to affect up to 2.5% of the world's population. Plaque-type psoriasis is the most common form of this disease.
Summary
To evaluate the clinical efficacy and safety of oral apremilast 30 mg twice a day (BID) compared with placebo, in subjects with moderate to severe plaque psoriasis at Week 16
Locations
- , , Belgium
- , , Czechia
- , , UK
- , , Hungary
- , , Estonia
- , , Germany
- , , Latvia
- , , Netherlands
View on source registry